PSP Research LLC Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0002106939
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 75 positions · Total reported value $187.88M · Top-10 concentration 88.0% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 78.9% · 1 new · 27 cut · 32 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -1.5% · vs SPY -3.6% · Prev Value $187.88M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -0.5% · vs SPY -2.6% · Latest Value $145.83M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2026 13F filing, PSP Research LLC disclosed 75 equity positions with a combined reported value of $187.88M. The filing implies a focused portfolio: its ten largest positions account for 88.0% of reported value. HoldingsHub classifies the profile as Small / Focused / High Turnover.
The largest disclosed positions as of Q2 2026 were XBI ($90.20M), SGOV ($70.47M), RPRX ($616.77K). By sector, the heaviest allocations are Health Care 14.2%, Industrials 0.1%. Versus the prior quarter, allocation shifted toward Other (+9.5pp) and away from Health Care (-9.5pp).
Versus the prior quarter, PSP Research LLC opened 1 new positions, trimmed 27 and fully exited 32, a turnover rate of 78.9% of positions. The portfolio's overlap with the prior quarter was 73% of names.
The largest new positions opened in Q2 2026 were LQDA ($398.65K), KRYS ($257.20K), AVBP ($244.60K).
Of the 32 positions fully exited versus the prior quarter, the largest were SERA ($4.87M), TYRA ($612.80K), CYTK ($547.05K).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
- LQDA LIQUIDIA CORPORATION · $398.65K
- KRYS KRYSTAL BIOTECH INC · $257.20K
- AVBP ARRIVENT BIOPHARMA INC · $244.60K
- JAZZ JAZZ PHARMACEUTICALS PLC · $233.98K
- RVMD REVOLUTION MEDICINES INC · $224.74K
- RYTM RHYTHM PHARMACEUTICALS INC · $222.06K
- DNLI DENALI THERAPEUTICS INC · $217.67K
- ARWR ARROWHEAD PHARMACEUTICALS IN · $211.93K
Fully Exited (vs previous quarter)
- SERA SERA PROGNOSTICS INC · prev qtr: $4.87M · history
- TYRA TYRA BIOSCIENCES INCORPORATED · prev qtr: $612.80K
- CYTK CYTOKINETICS INC · prev qtr: $547.05K
- AGIO AGIOS PHARMACEUTICALS INC COMP · prev qtr: $507.45K
- PRAX PRAXIS PRECISION MEDICINES I · prev qtr: $483.29K
- INBX INHIBRX BIOSCIENCES INC · prev qtr: $465.70K
- ERAS ERASCA INC · prev qtr: $280.35K
- CELC CELCUITY INC · prev qtr: $228.28K
Insider Transactions (Form 4)
Latest PSP Research LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
PSP Research LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 44 positions worth $145.83M in total. HoldingsHub carries 4 quarters of its filings (Q4 2025–Q3 2026).
Firm Snapshot
- SEC registration: 801-131402 (status: Approved), registered 2024-11-04
- Regulatory AUM (Form ADV): $178.64M as of 2026-07-01
Portfolio Structure
- 44 positions · $145.83M reported value (Q3 2026)
- Top 10 holdings = 95.0% of reported value
- Largest position: SGOV (ISHARES TR) at 48.3%
- Average position size: $3.31M
Sector Tilt
- Health Care 9.9%
- (classified holdings cover 10% of value)
Quarterly Activity
- Q3 2026: 1 new, 27 reduced, 32 exited
- 16 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
570.00K | $90.20M | 48.01% | Add | |
| 2 |
|
700.00K | $70.47M | 37.51% | Hold | |
| 3 |
|
11.00K | $616.77K | 0.33% | Hold | |
| 4 |
|
25.00K | $606.50K | 0.32% | Reduce | |
| 5 |
|
5.30K | $600.81K | 0.32% | Hold | |
| 6 |
|
641 | $594.70K | 0.32% | Hold | |
| 7 |
|
8.00K | $585.12K | 0.31% | Hold | |
| 8 |
|
14.00K | $583.38K | 0.31% | Hold | |
| 9 |
|
17.00K | $567.63K | 0.30% | Reduce | |
| 10 |
|
30.00K | $559.50K | 0.30% | Hold | |
| 11 |
|
23.00K | $556.60K | 0.30% | Reduce | |
| 12 |
|
10.00K | $549.40K | 0.29% | Reduce | |
| 13 |
|
7.00K | $547.89K | 0.29% | Reduce | |
| 14 |
|
6.80K | $539.17K | 0.29% | Hold | |
| 15 |
|
15.00K | $518.70K | 0.28% | Reduce | |
| 16 |
|
19.70K | $516.53K | 0.28% | Hold | |
| 17 |
|
30.00K | $509.10K | 0.27% | Hold | |
| 18 |
|
3.00K | $505.61K | 0.27% | Reduce | |
| 19 |
|
13.00K | $500.89K | 0.27% | Reduce | |
| 20 |
|
19.77K | $500.08K | 0.27% | Hold | |
| 21 |
|
6.00K | $489.42K | 0.26% | Hold | |
| 22 |
|
13.00K | $483.73K | 0.26% | Hold | |
| 23 |
|
15.14K | $480.73K | 0.26% | Hold | |
| 24 |
|
10.00K | $470.40K | 0.25% | Reduce | |
| 25 |
|
12.00K | $464.40K | 0.25% | Hold | |
| 26 |
|
4.00K | $458.68K | 0.24% | Reduce | |
| 27 |
|
20.00K | $444.20K | 0.24% | Hold | |
| 28 |
|
1.47K | $441.01K | 0.23% | Hold | |
| 29 |
|
7.00K | $440.58K | 0.23% | Hold | |
| 30 |
|
20.00K | $437.20K | 0.23% | Hold | |
| 31 |
|
8.00K | $435.28K | 0.23% | Reduce | |
| 32 |
|
11.00K | $411.62K | 0.22% | Hold | |
| 33 |
|
12.00K | $406.68K | 0.22% | Reduce | |
| 34 |
|
1.50K | $400.08K | 0.21% | Reduce | |
| 35 |
|
5.00K | $398.65K | 0.21% | New | |
| 36 |
|
12.00K | $392.64K | 0.21% | Hold | |
| 37 |
|
10.00K | $390.10K | 0.21% | Reduce | |
| 38 |
|
18.00K | $381.42K | 0.20% | Reduce | |
| 39 |
|
3.00K | $367.74K | 0.20% | Hold | |
| 40 |
|
10.00K | $364.10K | 0.19% | Reduce | |
| 41 |
|
7.00K | $355.25K | 0.19% | Hold | |
| 42 |
|
4.00K | $355.12K | 0.19% | Reduce | |
| 43 |
|
20.00K | $338.40K | 0.18% | Reduce | |
| 44 |
|
600 | $322.17K | 0.17% | Hold | |
| 45 |
|
5.00K | $319.75K | 0.17% | Reduce | |
| 46 |
|
6.00K | $314.37K | 0.17% | Hold | |
| 47 |
|
10.00K | $312.60K | 0.17% | Reduce | |
| 48 |
|
60.00K | $306.00K | 0.16% | Reduce | |
| 49 |
|
7.00K | $300.37K | 0.16% | Reduce | |
| 50 |
|
2.50K | $292.68K | 0.16% | Reduce | |
FAQ
What did PSP Research LLC buy in 2026-Q2?
In its 2026-Q2 13F filing, PSP Research LLC reported 75 equity positions worth $187.88M in aggregate; its largest disclosed positions were XBI ($90.20M), SGOV ($70.47M), RPRX ($616.77K).
How large is PSP Research LLC's portfolio?
PSP Research LLC reported $187.88M of long equity holdings across 75 positions as of 2026-Q2. Top-10 holdings account for 88.0% of reported value.
What is PSP Research LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.